Literature DB >> 7590486

Percutaneous gastrostomy for decompression in patients with advanced gynecologic malignancies.

M J Cunningham1, C Bromberg, D C Kredentser, M B Collins, J H Malfetano.   

Abstract

The objective of this study was to evaluate the use of percutaneous decompression gastrostomy in patients with gynecologic malignancies. Decompression gastrostomy tubes were inserted percutaneously in patients with recurrent gynecologic malignancies and small bowel obstruction or fistulae. The technique was evaluated for successful gastric decompression, acute and long-term complications, and palliation of symptoms. Twenty patients underwent placement of percutaneous gastrostomy tubes for decompression. Tube placement was successful in all patients, and all had significant relief of symptoms. There were no acute complications. Seven patients required replacement of tubes due to accidental dislodgment, balloon malfunction, obstruction or leakage around the tube, or systemic disease. Tubes remained in place for 7 to 184 days (mean 53). Sixty percent of patients returned home for palliative care for 3 to 173 days (mean 70). It was concluded that percutaneous decompression gastrostomy can be successfully performed in patients with recurrent gynecologic malignancies, and offers significant relief of symptoms and improvement in quality of life.

Entities:  

Mesh:

Year:  1995        PMID: 7590486     DOI: 10.1006/gyno.1995.0021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  [Palliative symptom control in malignant bowel obstruction due to advanced ovarian cancer].

Authors:  Kurt Alker; Franz Harnoncourt
Journal:  Wien Med Wochenschr       Date:  2006-05

2.  Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites.

Authors:  Colette Shaw; Roland L Bassett; Patricia S Fox; Kathleen M Schmeler; Michael J Overman; Michael J Wallace; Sanjay Gupta; Alda Tam
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

Review 3.  Current concepts in malignant bowel obstruction management.

Authors:  Eric Roeland; Charles F von Gunten
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

4.  Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.

Authors:  K S Rath; D Loseth; P Muscarella; G S Phillips; J M Fowler; D M O'Malley; D E Cohn; L J Copeland; E L Eisenhauer; R Salani
Journal:  Gynecol Oncol       Date:  2013-01-29       Impact factor: 5.482

Review 5.  Decompressive percutaneous gastrostomy tube use in gynecologic malignancies.

Authors:  Larissa Meyer; Bhavana Pothuri
Journal:  Curr Treat Options Oncol       Date:  2006-03

Review 6.  Treating nausea and vomiting in palliative care: a review.

Authors:  Paul Glare; Jeanna Miller; Tanya Nikolova; Roma Tickoo
Journal:  Clin Interv Aging       Date:  2011-09-12       Impact factor: 4.458

7.  Percutaneous endoscopic gastrostomy tube placement for end-stage palliation of malignant gastrointestinal obstructions.

Authors:  Anouar Teriaky; Jamie Gregor; Nilesh Chande
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485

8.  Survival, Healthcare Utilization, and End-of-life Care Among Older Adults With Malignancy-associated Bowel Obstruction: Comparative Study of Surgery, Venting Gastrostomy, or Medical Management.

Authors:  Elizabeth J Lilley; John W Scott; Joel E Goldberg; Christy E Cauley; Jennifer S Temel; Andrew S Epstein; Stuart R Lipsitz; Brittany L Smalls; Adil H Haider; Angela M Bader; Joel S Weissman; Zara Cooper
Journal:  Ann Surg       Date:  2018-04       Impact factor: 13.787

9.  MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.

Authors:  Ainhoa Madariaga; Jenny Lau; Arunangshu Ghoshal; Tomasz Dzierżanowski; Philip Larkin; Jacek Sobocki; Andrew Dickman; Kate Furness; Rouhi Fazelzad; Gregory B Crawford; Stephanie Lheureux
Journal:  Support Care Cancer       Date:  2022-03-10       Impact factor: 3.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.